Entire inactivated virus vaccine |
Powerful immune response; Safer than live attenuated virus |
Potential epitope modification by deactivation process |
Live attenuated virus vaccine |
Stronger immune response; Local antigen conservation; Copying natural infection |
Threat of persisting virulence, especially for immunocompromised persons |
Viral vector vaccine |
Stronger immune response; Local antigen preservation; Copying natural infection |
More intricated manufacturing procedure; Threat of genomic unification; Pre-existing immunity to the vector diminished the response |
Subunit vaccine |
Safe and well-tolerated |
Reduce immunogenicity: To improve immunogenicity, an adjuvant or conjugate is required to reduce immunogenicity |
Vaccine with viral-like particles |
Safe and well-tolerated; copying native virus conformation |
Reduce immunogenicity; More intricated development process |
DNA vaccine |
Safe and very much endured; Stable under room temperature; Extremely versatile to new microbe; Native antigen expression |
Reduce immunogenicity; Difficult introduction route; Threat of genomic integration |
RNA vaccine |
Safe and very much endured; Extremely versatile to new microorganism; Native antigen expression |
Reduce immunogenicity; Need of low temperature storage and shipping; Potential threat of RNA-incited interferon reaction (Li et al., 2020a, Li et al., 2020b, Li et al., 2020c) |
|
Some common adverse effects of COVID-19 vaccines |
Local side effects |
Redness, Inflammation, Pain at injection site |
Systemic side effects |
Pyrexia, Headache, Chills, Vomiting, Loose motions, New or worsening joint pain, Lymphadenopathy, Bell’s palsy |
Serious side effects |
Appendicitis, Myocardial infarction, Cerebrovascular accident, Shoulder injury, Lymphadenopathy on contralateral side |